Author

Xiaomei Liao

Early symptom improvement with risankizumab treatment in patients with moderately to severely active Crohn's disease: analysis from a Phase 2 study

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Julian Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Olivier Dewit, Ursula Seidler, Kyung-Jo Kim, Kristina Kligys, Kori Wallace, Xiaomei Liao, Wan-Ju Lee, Markus F. Neurath

Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: 3-year interim results from the ongoing Phase 2 open-label extension study

Marc Ferrante, Brian G. Feagan, Julian Panés, Filip Baert, Edouard Louis, Olivier Dewit, Arthur Kaser, Weijiang Rachel Duan, Dawn Gustafson, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: INTERIM RESULTS OF THE ONGOING PHASE 2 OPEN-LABEL EXTENSION STUDY

Marc Ferrante, Julian Panés, Filip Baert, Edouard Louis, Arthur Kaser, Dawn Gustafson, David Hall, Wulf O. Böcher, Ivona Herichova, Xiaomei Liao, Kori Wallace, Jasmina Kalabic, Geert R. D'Haens

Item 1 - 3 / 3
1